Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
